Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Capivasertib + docetaxel versus placebo + docetaxel in metastatic castration-resistant prostate cancer
NL-OMON53734Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Oct 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in prostate cancer (PCa) comparing Capivasertib + docetaxel with Placebo + docetaxel (2 arms). Primary endpoint: Overall survival. Planned start Oct 2022; status: not yet recruiting.
02
Drugs
capivasertibdocetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NL-OMON53734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53734.